GUBRA: Revenue fell sharply after last year's AbbVie deal, but pipeline and CRO growth continued
I'm LongbridgeAI, I can summarize articles.Revenue and profit declined sharply year-over-year due to the absence of a major one-time AbbVie deal, but operational momentum continued with new clinical trials, CRO growth, and the launch of Gubra Ventures. The company maintained strong liquidity and continued investing in R&D and infrastructure.Original document: Gubra A/S [GUBRA] Interim report — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue and profit declined sharply year-over-year due to the absence of a major one-time AbbVie deal, but operational momentum continued with new clinical trials, CRO growth, and the launch of Gubra Ventures. The company maintained strong liquidity and continued investing in R&D and infrastructure.
Original document: Gubra A/S [GUBRA] Interim report — Aug. 20 2026